Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia

被引:31
作者
Pingitore, Piero [1 ]
Lepore, Saverio Massimo [2 ]
Pirazzi, Carlo [1 ,3 ]
Mancina, Rosellina Margherita [1 ]
Motta, Benedetta Maria [1 ]
Valenti, Luca [4 ,5 ]
Berge, Knut Erik [6 ]
Retterstol, Kjetil [7 ,8 ]
Leren, Trond P. [6 ]
Wiklund, Olov [1 ,3 ]
Romeo, Stefano [1 ,2 ,3 ]
机构
[1] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden
[2] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Clin Nutr Unit, Catanzaro, Italy
[3] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden
[4] Fdn IRCCS Ca Granda Osped Policlin Milano, Internal Med, Milan, Italy
[5] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[6] Oslo Univ Hosp, Dept Med Genet, Unit Cardiac & Cardiovasc Genet, Oslo, Norway
[7] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway
[8] Oslo Univ Hosp, Lipid Clin, Rikshosp, Oslo, Norway
基金
瑞典研究理事会;
关键词
Type; 1; hyperlipoproteinemia; Hypertriglyceridemia; Missense and frameshift mutations; Familial lipoprotein lipase deficiency (FLD); Hyperchylomicronemia; HUMAN LIPOPROTEIN-LIPASE; MISSENSE MUTATION; BINDING; DOMAIN; CHYLOMICRONEMIA; ORLISTAT; THERAPY; PATIENT; ENZYME;
D O I
10.1016/j.jacl.2016.02.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Type 1 hyperlipoproteinemia is a rare autosomal recessive disorder most often caused by mutations in the lipoprotein lipase (LPL) gene resulting in severe hypertriglyceridemia and pancreatitis. OBJECTIVES: The aim of this study was to identify novel mutations in the LPL gene causing type 1 hyperlipoproteinemia and to understand the molecular mechanisms underlying the severe hypertriglyceridemia. METHODS: Three patients presenting classical features of type 1 hyperlipoproteinemia were recruited for DNA sequencing of the LPL gene. Pre-heparin and post-heparin plasma of patients were used for protein detection analysis and functional test. Furthermore, in vitro experiments were performed in HEIC293 cells. Protein synthesis and secretion were analyzed in lysate and medium fraction, respectively, whereas medium fraction was used for functional assay. RESULTS: We identified two novel mutations in the LPL gene causing type 1 hyperlipoproteinemia: a two base pair deletion (c.765_766delAG) resulting in a frameshift at position 256 of the protein (p.G256TfsX26) and a nucleotide substitution (c.1211 T > G) resulting in a methionine to arginine substitution (p.M404 R). LPL protein and activity were not detected in pre-heparin or post-heparin plasma of the patient with p.G256TfsX26 mutation or in the medium of HEK293 cells over expressing recombinant p.G256TfsX26 LPL. A relatively small amount of LPL p.M404 R was detected in both pre-heparin and post-heparin plasma and in the medium of the cells, whereas no LPL activity was detected. CONCLUSIONS: We conclude that these two novel mutations cause type 1 hyperlipoproteinemia by inducing a loss or reduction in LPL secretion accompanied by a loss of LPL enzymatic activity. (C) 2016 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:816 / 823
页数:8
相关论文
共 40 条
[1]   Combined immunodeficiency: The Middle East experience [J].
Al-Herz, Waleed ;
Al-Mousa, Hamoud .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (03) :658-660
[2]   Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons [J].
Beigneux, Anne P. ;
Davies, Brandon S. J. ;
Gin, Peter ;
Weinstein, Michael M. ;
Farber, Emily ;
Qiao, Xin ;
Peale, Franklin ;
Bunting, Stuart ;
Walzem, Rosemary L. ;
Wong, Jinny S. ;
Blaner, William S. ;
Ding, Zhi-Ming ;
Melford, Kristan ;
Wongsiriroj, Nuttaporn ;
Shu, Xiao ;
de Sauvage, Fred ;
Ryan, Robert O. ;
Fong, Loren G. ;
Bensadoun, Andre ;
Young, Stephen G. .
CELL METABOLISM, 2007, 5 (04) :279-291
[3]   Type 1 hyperlipoproteinemia due to a novel deletion of exons 3 and 4 in the GPIHBP1 gene [J].
Berge, Knut Erik ;
Retterstol, Kjetil ;
Romeo, Stefano ;
Pirazzi, Carlo ;
Leren, Trond P. .
ATHEROSCLEROSIS, 2014, 234 (01) :30-33
[4]  
Brunzell JD., 2014, GENEREVIEWS
[5]   Gene therapy enters the pharma market: The short story of a long journey [J].
Buening, Hildegard .
EMBO MOLECULAR MEDICINE, 2013, 5 (01) :1-3
[6]   The nonsense-mediated decay RNA surveillance pathway [J].
Chang, Yao-Fu ;
Imam, J. Saadi ;
Wilkinson, Miles E. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2007, 76 :51-74
[7]   STRUCTURE OF THE HUMAN LIPOPROTEIN-LIPASE GENE [J].
DEEB, SS ;
PENG, RL .
BIOCHEMISTRY, 1989, 28 (10) :4132-4135
[8]  
EMMERICH J, 1992, J BIOL CHEM, V267, P4161
[9]   FAMILIAL LIPOPROTEIN-LIPASE AND APOLIPOPROTEIN C-II DEFICIENCY - LIPOPROTEIN AND APOPROTEIN ANALYSIS, ADIPOSE-TISSUE AND HEPATIC LIPOPROTEIN-LIPASE LEVELS IN 7 PATIENTS AND THEIR 1ST DEGREE RELATIVES [J].
FELLIN, R ;
BAGGIO, G ;
POLI, A ;
AUGUSTIN, J ;
BAIOCCHI, MR ;
BALDO, G ;
SINIGAGLIA, M ;
GRETEN, H ;
CREPALDI, G .
ATHEROSCLEROSIS, 1983, 49 (01) :55-68
[10]  
Foubert L, 1996, PRESSE MED, V25, P207